Pharmaceutical Technology

JANUARY 17, 2023

While tirzepatide requires weekly administration, bimagrumab is administered once every four weeks, which should have positive implications on patient compliance. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.

Development 130

Development Compliance Trials Marketing 130

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). Lilly reported its stellar earnings in a release this week.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. Related: Eli Lilly’s Type 2 Diabetes Shot Tirzepatide Emerges Winner Against Semaglutide.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. compared to a 5.1%

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246